Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefdinir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 0.79 |
| ▸ | APAF1 | O14727 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.79 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.79 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.79 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.78 |
| ▸ | MMP2 | P08253 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefdinir SCHEMBL36995 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL6820723 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL2221924 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL5919457 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL3297328 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL16072816 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL1559599 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL36996 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL4114437 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL4114446 | 1.00 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452990-B2 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2008-11-18 | — | — | US | claimed |
| US-20060135761-A1 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2006-06-22 | — | — | US | claimed |
| EP-1575913-A1 | NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES | Lupin Limited (IN) | 2005-09-21 | — | — | EP | claimed |
| WO-2004058695-A1 | NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES | LUPIN LIMITED (IN) | 2004-07-15 | — | — | WO | claimed |
| US-7741478-B2 | Salts in the preparation of cephalosporin antibiotics | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2010-06-22 | — | — | US | disclosed |
| US-20080306256-A1 | Salts in the Preparation of Cephalosporin Antibiodies | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-7452990-B2 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2008-11-18 | — | — | US | disclosed |
| US-7244842-B2 | Amorphous hydrate of a cephalosporin antibiotic | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2007-07-17 | — | — | US | disclosed |
| EP-1765833-A2 | NEWS SALTS IN THE PREPARATION OF CEPHALOSPORIN ANTIBIOTICS | Orchid Chemicals and Pharmaceuticals Limited (IN) | 2007-03-28 | — | — | EP | disclosed |
| US-20060149056-A1 | Stable bioavailable crystalline form of cefdinir and a process for the preparation thereof | LUPIN LTD (IN) | 2006-07-06 | — | — | US | disclosed |
| US-20060135761-A1 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2006-06-22 | — | — | US | disclosed |
| US-20060094703-A1 | Novel amorphous hydrate of a cephalosporin antibiotic | ORCHID CHEMICALS AND PHARMACEUTICALS LTD. (IN) | 2006-05-04 | — | — | US | disclosed |
| EP-1074554-A2 | 7-acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-1074553-A1 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-0761671-A1 | Cephem derivatives | Eisai Co., Ltd. (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5604217-A | CEPHALOSPORIN ANTIBIOTICS | EISAI CO., LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| US-5587473-A | BLOCKING; CONDENSATION; DEBLOCKING | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5563265-A | BACTERICIDES | EISAI CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| US-5559225-A | ANTIBIOTICS | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| EP-0484966-A2 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306256-A1 | Salts in the Preparation of Cephalosporin Antibiodies | ABCB11, SLC10A1, NISCH | TDP1 4358/4885MAPT 3770/4885ABCC4 178/4885 |
| US-20060094703-A1 | Novel amorphous hydrate of a cephalosporin antibiotic | C1R, CEP170, Q6ZSR9 | TDP1 3355/4885MAPT 1249/4885ABCC4 808/4885 |
| US-20060135761-A1 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | CYP2F1, CYP2W1, CYP4F11 | TDP1 4109/4885MAPT 4597/4885ABCC4 2262/4885 |
| US-20060149056-A1 | Stable bioavailable crystalline form of cefdinir and a process for the preparation thereof | DCXR, CYP4F8, ABCG2 | TDP1 4417/4885MAPT 2036/4885ABCC4 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.